Market Trends of Enzyme Inhibitors Industry
Kinase Inhibitors Segment Is Expected to Hold a Significant Share in the Enzyme Inhibitors Market
- Kinase inhibitors are a class of enzyme inhibitors that obstruct the activity of one or more protein kinase enzymes. Protein kinases are enzymes that add a phosphate group to a protein, altering its function. Certain types of kinases are more active in various cancer cells, and blocking these kinases may help impede cancer cell growth.
- The escalating prevalence of target diseases such as cancer and cardiovascular disease, as well as the increase in kinase inhibitors for treating these diseases, have been driving the growth of this segment. For instance, a study published by the British Heart Foundation in February 2023 indicated that around 7.6 million people in the United Kingdom were living with heart disease in 2021.
- Moreover, an article published by the National Library of Medicine (NLM) in November 2022 revealed that 72 Food and Drug Administration (FDA)-approved therapeutic agents target about two dozen protein kinases, with three of these drugs being approved in 2022. Of the approved drugs, twelve target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), sixteen block nonreceptor protein-tyrosine kinases, and 40 target receptor protein-tyrosine kinases. Sixty-two of these drugs are prescribed for the treatment of neoplasms.
- Four drugs (abrocitinib, baricitinib, tofacitinib, and upadacitinib) are used to treat inflammatory diseases (atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis). The increasing availability of kinase inhibitors for treating target diseases is expected to drive segmental growth.
- Furthermore, acquisitions, partnerships, mergers, and collaborations by key players in the market are expected to boost the segmental market. For example, in March 2021, Pfizer Inc. received United States Food and Drug Administration (US FDA) approval for a supplemental new drug application (sNDA) for LORBRENA (lorlatinib), a TKI, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.
- Thus, all of the aforementioned factors, including the growing prevalence of target diseases such as cancer and cardiovascular disease, the increase in kinase inhibitors for treating these diseases, and the mergers and partnerships of key players, are expected to contribute to the growth of this segment over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America Is Expected to Hold a Significant Share in the Enzyme Inhibitors Market
- The growth of North America's market is driven by several factors, including a well-established healthcare infrastructure and increased government initiatives that offer attractive reimbursement policies. Additionally, the rising incidence of cancer is a significant factor driving the enzyme inhibitors market's development.
- According to the American Cancer Society's 2023 update, more than 1.9 million new cancer cases are expected to be diagnosed in the United States this year, excluding basal and squamous cell skin cancers and carcinoma in situ, except for the urinary bladder. Similarly, the Canadian Cancer Statistics 2021 report released in November 2021 estimated that two out of five Canadians would be diagnosed with cancer in their lifetime, with 229,200 Canadians diagnosed in 2021. Consequently, the growing prevalence of cancer in North America is expected to have a substantial impact on the market's expansion.
- In addition, the introduction of innovative products using enzyme inhibitors to treat multiple conditions is expected to drive market growth. For example, in July 2021, Ocular Therapeutix Inc. initiated the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) to treat wet age-related macular degeneration (wet AMD). Additionally, in June 2022, Pfizer Inc. submitted a New Drug Application (N.D.A.) to the USFDA for the approval of PAXLOVID (nirmatrelvir and ritonavir tablets) for high-risk patients who are likely to progress to severe illness from COVID-19. As a result, ongoing clinical trial processes in this market are expected to promote its growth.
- In summary, the factors mentioned above, including a developed healthcare infrastructure, increased government initiatives, and the growing incidence of cancer, are expected to contribute significantly to North America's strong growth in this market over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
